Figure S4. Activation of c-Abl and Arg reduces expression of NM23H1. (a,b) Cell lines expressing activated c-Abl/ Arg (Fig. 3a,b) were treated with imatinib (10μM) **(a),** nilotinib (5μM) **(b)** or were transfected with scrambled (Scr), c-Abl or Arg siRNAs (2 independent sets) **(c)**. NM23-H1 and α-tubulin or β-actin expression were detected in cell lysates by western blot after 8h treatment **(a,b)** or 3 days after transfection **(c)**, and bands quantitated with ImageQuant. **(d)** Low-invasive WM164 melanoma cells were transiently transfected with c-Abl-PP and Arg-PP (constitutively active forms). NM23-H1 and α-tubulin expression were determined 3 days after transfection. **(e)** cDNA was prepared from RNA from 435s cells expressing c-Abl or Arg siRNAs, and subjected to semi-quantitative RT-PCR using NM23-H1 primers and internal control β-actin primers. For all subfigures, relative NM23-H1 expression (relative to loading control) was graphed (Mean±SEM for 3-4 independent experiments). *p<0.05, **p<0.01, ***p<0.001 using one-sample t-tests.